Immune checkpoint inhibitors continuation beyond progression as second-line treatment for extensive-stage small-cell lung cancer: a real-world, multicenter analysis
In patients with ES-SCLC who exhibit disease progression after 1L chemoimmunotherapy, continuation of ICIs significantly improves survival and tumor response while achieving a manageable safety profile. Therefore, ICIs continuation may be considered a viable strategy in 2L settings.
Authors
- Lujun Zhao (ORCID: https://orcid.org/0000-0001-5960-0201)
- Ye Lv (ORCID: https://orcid.org/0000-0001-7920-074X)
- Rui Zi
- Yan Wang
- Haixia Zhang (ORCID: https://orcid.org/0000-0002-4929-9686)
- Jiao Zhang (ORCID: https://orcid.org/0000-0003-3874-6505)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.3389/fimmu.2025.1666373
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05